Scopus
🔓 Açık Erişim YÖKSİS Eşleşti
Impact of low molecular weight heparin administration on the clinical course of the COVID-19 disease
Turkish Journal of Medical Sciences · Ocak 2021
YÖKSİS Kayıtları
Impact of low molecular weight heparin administration on the clinical course of the COVID-19 disease
TURKISH JOURNAL OF MEDICAL SCIENCES · 2021 SCI-Expanded
PROFESÖR RECAİ ERGÜN →
Impact of low molecular weight heparin administration on the clinical course of the COVID-19 disease
TURKISH JOURNAL OF MEDICAL SCIENCES · 2021 SCI-Expanded
DOÇENT DİLEK ERGÜN →
Impact of low molecular weight heparin administration on the clinical course of the COVID-19 disease
TURKISH JOURNAL OF MEDICAL SCIENCES · 2021 SCI-Expanded
PROFESÖR UĞUR ARSLAN →
Impact of low molecular weight heparin administration on the clinical course of the COVID-19 disease
TURKISH JOURNAL OF MEDICAL SCIENCES · 2021 SCI-Expanded
PROFESÖR FİKRET KANAT →
Impact of low molecular weight heparin administration on the clinical course of the COVID-19 disease
TURKISH JOURNAL OF MEDICAL SCIENCES · 2021 SCI-Expanded
PROFESÖR FİKRET KANAT →
Impact of low molecular weight heparin administration on the clinical course of the COVID-19 disease
TURKISH JOURNAL OF MEDICAL SCIENCES · 2021 SCI-Expanded
DOÇENT BURCU YORMAZ →
Makale Bilgileri
DergiTurkish Journal of Medical Sciences
Yayın TarihiOcak 2021
Cilt / Sayfa51 · 28-38
Scopus ID2-s2.0-85102300609
Erişim🔓 Açık Erişim
Özet
Background: Lymphopenia is the most important criterion of mortality and discharging feature for patients infected with coronavirus disease 2019 (COVID-19). This study aimed to investigate the clinical impact of a low molecular weight heparin (LMWH) treatment on the clinical course of COVID-19. Materials and methods: Patients’ clinical symptoms, radiologic outcomes, hematologic, biochemical, D-dimer, and C-reactive protein (CRP) results were obtained from their medical records. Participants were separated into 2 groups: one was treated with LMWH and the other was not. Improvement in the patients was compared before and after treatment. Results: Ninety-six patients who were diagnosed with COVID-19 between April and May 2020 were retrospectively analyzed. The multivariable analysis showed that the count of lymphocytes, D-dimer, and CRP levels were significantly improved in the LMWH group, as compared to the control group (OR, (95% CI) 0.628 (0.248–0.965), P < 0.001); OR, (95% CI) 0.356 (0.089–0.674), P < 0.001, respectively). The area under the receiver operating characteristic (ROC) curve analysis was AUC: 0.679 ± 0.055, 0.615 ± 0.058, and 0.633 ± 0.057, respectively; the β-value was found to be –1.032, –0.026, and –0.465, respectively. Conclusion: The LMWH treatment group demonstrated better laboratory findings, including recovery in the lymphocyte count, CRP, and D-dimer results.
Yazarlar (6)
1
Burcu Yormaz
2
Dilek Ergün
3
Baykal Tulek
4
Recai Ergün
5
Ugur Arslan
6
F. Kanat
Anahtar Kelimeler
Antiinflammatory
Coronavirus disease-19
Heparin
Lymphocyte
Kurumlar
Selçuk Tip Fakültesi
Konya Turkey
Metrikler
3
Atıf
6
Yazar
4
Anahtar Kelime